Dynavax Technologies (DVAX) announced that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax’s intratumoral TLR9 agonist, in combination with KEYTRUDA, an anti-PD-1 therapy developed by Merck (MRK). Data on patients with advanced melanoma who are naive to anti-PD-1 therapy is the subject of a poster presentation and will be highlighted in a poster discussion session at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018 in Chicago, IL. The abstract for the poster titled “Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD1 therapy” has been posted on the 2018 ASCO Annual Meeting website, here. The abstract summarizes efficacy data on 25 patients that were available at the time of abstract submission in early February and shows an overall response rate of 60%. The combination reported low rates of Grade 3-4 treatment-related adverse events and no evidence of an increased rate of immune-related adverse events. The poster at ASCO in June will present efficacy data from over 50 patients comparing two doses of SD-101, 2mg in 1-4 lesions versus 8mg in a single lesion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.